Adalimumab (Humira®) dosing frequency in RA patient assistance programs

被引：0
|
作者：
McAndrews, MB [1 ]
Kosch, K [1 ]
Kern, C [1 ]
Holly, K [1 ]
Haas, JN [1 ]
机构：
[1] Abbott Labs, Publ Hlth Policy & Strategy, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：265 / 266
页数：2
相关论文
共 50 条
  • [21] Improvement of the individual ACR components in ACR20 responders in an adalimumab (HUMIRA™) RA clinical trial
    Furst, DE
    Weinblatt, ME
    Kavanaugh, A
    Kalden, JR
    Wells, AF
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S106 - S107
  • [22] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [23] Assessment of disease activity and treatment response to adalimumab (HUMIRA®) in RA with the simplified disease activity index (SDAI).
    Smolen, JS
    Breedveld, FC
    Schiff, MH
    Kalden, JR
    Emery, P
    Segurado, OG
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S190 - S191
  • [24] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [25] Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA®) plus methotrexate vs. adalimumab alone or methotrexate alone:: The PREMIER study.
    Breedveld, FC
    Kavanaugh, AF
    Cohen, SB
    Pavelka, K
    van Vollenhoven, R
    Perez, JL
    Spencer-Green, GT
    Weisman, MH
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4096 - 4097
  • [26] Sustained 5-year efficacy of adalimumab (HUMIRA™) monotherapy in DMARD-refractory rheumatoid arthritis (RA).
    van de Putte, LBA
    Rau, R
    Burmester, GR
    Hartz, D
    Fischkoff, SA
    Kupper, H
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S314
  • [27] A comparison of the SDAI and DAS28 as measures of response in adalimumab (HUMIRA™) clinical trials in rheumatoid arthritis (RA).
    Smolen, JS
    Breedveld, FC
    Schiff, MH
    Kalden, JR
    Emery, P
    Gelhorn, AJ
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S107 - S107
  • [28] The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
    van den Bosch, Filip
    Wassenberg, Siegfried
    Haraoui, Boulos
    Zueger, Patrick
    Wu, Meijing
    Galindo, Ivan Lagunes
    Ostor, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [29] The cost utility of adalimumab (HUMIRA®) and infliximab (REMICADE) in the treatment of patients with early rheumatoid arthritis (RA):: US analysis
    Davies, AS
    Hutton, J
    Cifaldi, MA
    Pang, F
    Spencer-Green, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 393 - 393
  • [30] Sustained radiographic inhibition with adalimumab (HUMIRA™) over 2 years in patients with long standing rheumatoid arthritis (RA).
    Keystone, EC
    Kavanaugh, A
    Sharp, JT
    Spencer-Green, GT
    Fischkoff, SA
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S315 - S315
12345